Uncovering heterogeneous cognitive trajectories in relapsing-remitting multiple sclerosis: a longitudinal study

被引:0
|
作者
London, Frederic [1 ,4 ]
De Haan, Alice [2 ]
Benyahia, Zohra [2 ]
Landenne, Gaetane [2 ]
Duprez, Thierry [3 ]
van Pesch, Vincent [2 ]
El Sankari, Souraya [2 ]
机构
[1] Univ Catholique Louvain UCLouvain, Dept Neurol, CHU UCL Namur Site Godinne, Yvoir, Belgium
[2] Univ Catholique Louvain UCLouvain, Dept Neurol, Clin Univ St Luc, Brussels, Belgium
[3] Univ Catholique Louvain UCLouvain, Dept Radiol, Clin Univ St Luc, Brussels, Belgium
[4] CHU UCL Namur, Dept Neurol, 1 Ave G Therasse, B-5530 Yvoir, Belgium
关键词
DECLINE; MRI; RESERVE; DYSFUNCTION; IMPAIRMENT; VALIDATION; PREDICTORS;
D O I
10.1007/s13760-025-02754-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundCognitive impairment (CI) frequently occurs in relapsing-remitting multiple sclerosis (RRMS) and is assumed to be irreversible. Recent longitudinal studies highlighted the heterogeneity of CI in RRMS, challenging the traditional view of inevitable progression. Longitudinal studies exploring the baseline determinants of future cognitive decline are limited, and none yet explored the predictive value of patient-reported outcome measures (PROMs).ObjectiveTo explore the evolutionary patterns of cognitive status in a cohort of RRMS patients initiating a new disease modifying treatment, and to determine whether PROMs may have a predictive value for future cognitive decline.MethodsThis prospective study is a 36-month follow-up of 59 RRMS patients who underwent yearly a comprehensive, multiparametric assessment combining clinical, neuropsychological, MRI-derived metrics and a set of self-reported questionnaires. Lesion load and brain volumes were analyzed and processed by the automated MSmetrix (R) software (Icometrix (R), Leuven, Belgium). A longitudinal logistic regression analysis was performed to investigate baseline predictors of future cognitive decline.ResultsA total of 33 (56%) and 17 (35%) patients were defined as cognitively impaired at baseline and at the end of the study, respectively. Of these 33 patients, 20 showed either improvement and/or impairment in fewer cognitive domains at 36-month follow-up. Baseline physical disability as measured by EDSS was the best predictor for future cognitive decline (OR: 2.17; p = 0.03, 95% confidence interval = 1.07-4.38). None of the PROMs variables contributed to predict further cognitive decline.ConclusionsOur findings highlight the importance of considering the evolution of CI in MS as a dynamic phenomenon with a substantial heterogeneity.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Evidence of a cognitive reserve in early relapsing-remitting multiple sclerosis
    Bonnet, M
    Deloire, M
    Salort, E
    Arimone, Y
    Dousset, V
    Petry, K
    Brochet, B
    MULTIPLE SCLEROSIS, 2005, 11 : S3 - S4
  • [32] Cognitive function and oral health in relapsing-remitting multiple sclerosis
    Manchery, Nithin
    Henry, Julie D.
    Swayne, Andrew
    Beer, Reuben
    Blum, Stefan
    Nangle, Matthew R.
    CLINICAL ORAL INVESTIGATIONS, 2022, 26 (03) : 2899 - 2907
  • [33] MRI AND COGNITIVE PATTERNS IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS
    PUGNETTI, L
    MENDOZZI, L
    MOTTA, A
    CATTANEO, A
    BISERNI, P
    CAPUTO, D
    CAZZULLO, CL
    VALSECCHI, F
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1993, 115 : S59 - S65
  • [34] Cognitive deterioration in patients with initial relapsing-remitting multiple sclerosis
    Genov, K.
    Dimitrova, M.
    JOURNAL OF NEUROLOGY, 2012, 259 : S195 - S196
  • [35] Cognitive function in Turkish patients with relapsing-remitting multiple sclerosis
    Gedik, Z.
    Idiman, E.
    Ozakbas, S.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (07) : 981 - 982
  • [36] Depression in relapsing-remitting multiple sclerosis
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Moreira, MA
    Barao-Cruz, AM
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (3A) : 591 - 595
  • [37] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [38] Autohemotherapy for relapsing-remitting multiple sclerosis
    Mubaidin, AF
    Horani, KA
    Dehayyat, MA
    Shehab, M
    Abu-Ruman, IA
    Shurbaji, AA
    Kurdi, A
    Hiari, M
    Khakish, M
    Harahsheh, O
    Dabbas, M
    NEUROLOGY, 2001, 56 (08) : A75 - A75
  • [39] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [40] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645